Syon Med Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 Cr
as on 24-10-2024
- Revenue 68.61%
(FY 2023)
- Profit 142.66%
(FY 2023)
- Ebitda 97.64%
(FY 2023)
- Net Worth 118.79%
(FY 2023)
- Total Assets 9.15%
(FY 2023)
About Syon Med
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.00 Cr.
Vinay Sharma and Megha Lawania serve as directors at the Company.
- CIN/LLPIN
U33111DL2015PTC282866
- Company No.
282866
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jul 2015
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Syon Med Private Limited offer?
Syon Med Private Limited offers a wide range of products and services, including Eye Diagnosis & Surgery Instruments, Eye Testing Machines, Ophthalmic Surgical Instruments, Medical & Surgical Clothing, OT Linen, Optical Components, Metallurgical & Lab Microscopes, Medical Microscope, Common Disease Medicines, Eye Drops.
Who are the key members and board of directors at Syon Med?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinay Sharma  | Additional Director | 25-Feb-2022 | Current |
| Megha Lawania | Director | 15-Jul-2015 | Current |
Financial Performance of Syon Med.
Syon Med Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 68.61% increase. The company also saw a substantial improvement in profitability, with a 142.66% increase in profit. The company's net worth Soared by an impressive increase of 118.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Syon Med?
In 2023, Syon Med had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rudr Meditronics Private LimitedActive 9 years 6 monthsVinay Sharma and Megha Lawania are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 22 Mar 2024 | ₹3.00 Cr | Open |
How Many Employees Work at Syon Med?
Unlock and access historical data on people associated with Syon Med, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Syon Med, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Syon Med's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
